Characterization of a novel microfluidic platform for the isolation of rare single cells to enable CTC analysis from head and neck squamous cell carcinoma patients. Issue 5 (6th April 2022)

• Record Type: Journal Article
• Authors: Stiefel, Janis; Freese, Christian; Sriram, Ashwin; Alebrand, Sabine; Srinivas, Nalini; Sproll, Christoph; Wandrey, Madita; Gül, Désirée; Hagemann, Jan; Becker, Jürgen C.; Baßler, Michael
• Is Part Of: Engineering in life sciences. Volume 22:Issue 5(2022)
• Page Start: 391
• Page End: 406
• Publication Date: 2022-04-06
• Subjects: automation -- liquid biopsy -- microfluidics -- precision medicine -- tumor diagnostics; Bioengineering -- Periodicals; 660.605
• DOI: 10.1002/elsc.202100133
• Languages: English
• ISSNs: 1618-0240

Abstract

Abstract: Detailed examination of tumor components is leading‐edge to establish personalized cancer therapy. Accompanying research on cell‐free DNA, the cell count of circulating tumor cells (CTCs) in patient blood is seen as a crucial prognostic factor. The potential of CTC analysis is further not limited to the determination of the overall survival rate but sheds light on understanding inter‐ and intratumoral heterogeneity. In this regard, commercial CTC isolation devices combining an efficient enrichment of rare cells with a droplet deposition of single cells for downstream analysis are highly appreciated. The Liquid biopsy platform CTCelect was developed to realize a fully‐automated enrichment and single cell dispensing of CTCs from whole blood without pre‐processing. We characterized each process step with two different carcinoma cell lines demonstrating up to 87 % enrichment (n = 10) with EpCAM coupled immunomagnetic beads, 73 % optical detection and dispensing efficiency (n = 5). 40 to 56.7 % of cells were recovered after complete isolation from 7.5 ml untreated whole blood (n = 6). In this study, CTCelect enabled automated dispensing of single circulating tumor cells from HNSCC patient samples, qPCR‐based confirmation of tumor‐related biomarkers and immunostaining. Finally, the platform was compared to commercial CTC isolation technologies to highlight advantages and limitations of CTCelect . This system offers new possibilities for single cell screening in cancer diagnostics, individual therapy approaches and real‐time monitoring.